Introduction: The importance of secondary hyperparathyroidism (SHPT) are frequently neglected in hemodialysis (HD) centers.Objectives: The aim of this study is to determine the prevalence of SHPT in a group of ESRD patients under routine HD.Patients and Methods: From May 2016 to August 2016, this cross sectional study was conducted on ESRD patients undergoing HD in our HD center in Beharlou hospital, Tehran province, Iran. Blood samples were obtained prior to HD session to assess laboratory parameters including intact PTH level, serum calcium, phosphorus, and alkaline phosphatase. Immunoradiometric assay was used to measure serum intact PTH (iPTH) level.Results: Forty-five HD patients, including 19 females (42.2%) with mean age of 60±14.3 years were enrolled to the study. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for mineral metabolism, 60% of our patients (n = 27) had accepted normal range of serum calcium (8.4 to 9.5 mg/dL) while 28.9% of patients had serum calcium of below 8.4 mg/dL. Around 60% of our patients (n = 27) had accepted normal range of serum phosphorus (3.5 to 5.5 mg/dL) while serum phosphorus above 5.5 mg/dL was detected in 31.1% of HD patients. Sixteen patients (35.55%) had iPTH levels between 150-300 ρg/mL which was in the accepted ranges for iPTH levels among HD patients. Seventeen patients (37.78%) had iPTH levels above accepted range.Conclusion: This study showed that PTH abnormalities and disorders of mineral metabolism are common among patients with ESRD. It is crucial to better understand the pathogenesis and treatment of these disorders among ESRD patients.Keywords: Hemodialysis, Parathyroid hormone, Secondary hyperparathyroidism, End-stage renal disease, Parathormone, Chronic kidney disease, Parathormone
{"title":"Secondary hyperparathyroidism among end-stage renal disease patients in Beharlou hospital, Tehran province, Iran","authors":"S. Movahed, S. Mousavi, M. Faramarzi","doi":"10.15171/JPD.2018.20","DOIUrl":"https://doi.org/10.15171/JPD.2018.20","url":null,"abstract":"Introduction: The importance of secondary hyperparathyroidism (SHPT) are frequently neglected in hemodialysis (HD) centers.Objectives: The aim of this study is to determine the prevalence of SHPT in a group of ESRD patients under routine HD.Patients and Methods: From May 2016 to August 2016, this cross sectional study was conducted on ESRD patients undergoing HD in our HD center in Beharlou hospital, Tehran province, Iran. Blood samples were obtained prior to HD session to assess laboratory parameters including intact PTH level, serum calcium, phosphorus, and alkaline phosphatase. Immunoradiometric assay was used to measure serum intact PTH (iPTH) level.Results: Forty-five HD patients, including 19 females (42.2%) with mean age of 60±14.3 years were enrolled to the study. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for mineral metabolism, 60% of our patients (n = 27) had accepted normal range of serum calcium (8.4 to 9.5 mg/dL) while 28.9% of patients had serum calcium of below 8.4 mg/dL. Around 60% of our patients (n = 27) had accepted normal range of serum phosphorus (3.5 to 5.5 mg/dL) while serum phosphorus above 5.5 mg/dL was detected in 31.1% of HD patients. Sixteen patients (35.55%) had iPTH levels between 150-300 ρg/mL which was in the accepted ranges for iPTH levels among HD patients. Seventeen patients (37.78%) had iPTH levels above accepted range.Conclusion: This study showed that PTH abnormalities and disorders of mineral metabolism are common among patients with ESRD. It is crucial to better understand the pathogenesis and treatment of these disorders among ESRD patients.Keywords: Hemodialysis, Parathyroid hormone, Secondary hyperparathyroidism, End-stage renal disease, Parathormone, Chronic kidney disease, Parathormone","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"66 1","pages":"64-67"},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78804627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bita Omidvar, A. Ghorbani, M. Tamadon, Zahra Sadeghian Broujeni
Introduction: The existence of a relationship between the level of serum parathyroid hormone (PTH) and bone density can be a warning sign in hemodialysis patients.Objectives: In the studies conducted so far, the relationship between these two factors has not been specifically investigated. Hence, this study was aimed to exclusively evaluate the levels of serum PTH hormone and bone density.Patients and Methods: In this cross sectional study, 85 eligible chronic hemodialysis patients aged over 18 years old, who had underwent hemodialysis a minimum of two times a week for at least six months were enrolled in the study. Serum intact PTH, 25 OH-vitamin D3, CBC-calcium, phosphorus, alkaline phosphatase, albumin, and VBG were measured. Additionally, lumbar radiographic profile and densitometry tests were conducted for patients.Results: The mean age of patients was 52.9 years (20 to 86 years old). Of them, 43 patients were male (50.6%). There was a significant correlation between age and the decrease in bone density (p =0.004). There was a significant relationship between different groups of bone density and serum vitamin D3 level (P < 0.05). Based on the results of Z standard, a significant difference between the mean levels of intact PTH in different groups of bone density was seen (p = 0.037).Conclusion: The prevalence of osteopenia and osteoporosis in hemodialysis patients is high. In addition, the decrease in bone density is associated with high levels of parathyroid hormone. While, this association is mainly associated with Z score, it is necessary to investigate the secondary causes of this condition.
{"title":"Relationship of bone density with serum parathyroid hormone in hemodialysis patients; a single center study","authors":"Bita Omidvar, A. Ghorbani, M. Tamadon, Zahra Sadeghian Broujeni","doi":"10.15171/JPD.2018.19","DOIUrl":"https://doi.org/10.15171/JPD.2018.19","url":null,"abstract":"Introduction: The existence of a relationship between the level of serum parathyroid hormone (PTH) and bone density can be a warning sign in hemodialysis patients.Objectives: In the studies conducted so far, the relationship between these two factors has not been specifically investigated. Hence, this study was aimed to exclusively evaluate the levels of serum PTH hormone and bone density.Patients and Methods: In this cross sectional study, 85 eligible chronic hemodialysis patients aged over 18 years old, who had underwent hemodialysis a minimum of two times a week for at least six months were enrolled in the study. Serum intact PTH, 25 OH-vitamin D3, CBC-calcium, phosphorus, alkaline phosphatase, albumin, and VBG were measured. Additionally, lumbar radiographic profile and densitometry tests were conducted for patients.Results: The mean age of patients was 52.9 years (20 to 86 years old). Of them, 43 patients were male (50.6%). There was a significant correlation between age and the decrease in bone density (p =0.004). There was a significant relationship between different groups of bone density and serum vitamin D3 level (P < 0.05). Based on the results of Z standard, a significant difference between the mean levels of intact PTH in different groups of bone density was seen (p = 0.037).Conclusion: The prevalence of osteopenia and osteoporosis in hemodialysis patients is high. In addition, the decrease in bone density is associated with high levels of parathyroid hormone. While, this association is mainly associated with Z score, it is necessary to investigate the secondary causes of this condition.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"1 1","pages":"57-63"},"PeriodicalIF":0.0,"publicationDate":"2017-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90711388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Chronic kidney disease (CKD) is associated with bone and mineral metabolism disorders.Objectives: This investigation studied the bone mineral density (BMD) and bone metabolism biochemical markers in patients with CKD at the hemodialysis treatment among a group of Iranian hemodialysis patients. We also sought to test the possible association of risk factors and biochemical parameters with BMD.Patients and Methods: In this cross sectional study, 77 patients with CKD stage 5D at the hemodialysis treatment. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the anteroposterior lumbar spine (LS) (L1-L4) and left proximal femur. Biochemical markers, including calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), serum specific alkaline phosphatase (ALP) and 25-hydroxy-vitamin D (25(OH)D) were measured to assess BMD loss.Results: Around two (2.6%) patients had normal levels of 25(OH) D (mean levels 17.67 ± 11.66 nmol/l). We found a reduction of BMD in comparison with age and gender-matched normal population values at the femoral neck (FN) (T-score = -1.92 ± 1.29), at the total hip (TH) (T-score = -1.79 ± 1.25) and at the lumbar spine (LS) (T-score = -1.55 ± 1.84). The prevalence of T-scores ≤ -2.5 SD was 28.6%, 35.1% and 13.0% according to LS, FN and three bone sites T scores respectively. BMD negatively correlated: with age at the proximal femur, with serum ALP at the lumbar spine and with age of menopause at the femoral neck.Conclusion: Patients with end-stage renal disease at the hemodialysis treatment had a high prevalence of osteoporosis in the general population. Bone mineral density at the all bone sites was below the expected average for gender and age.
{"title":"Bone mineral density and bone metabolism biochemical markers in patients with chronic kidney disease at the hemodialysis treatment","authors":"M. Tamadon, J. Moghimi, V. Semnani","doi":"10.15171/JPD.2018.18","DOIUrl":"https://doi.org/10.15171/JPD.2018.18","url":null,"abstract":"Introduction: Chronic kidney disease (CKD) is associated with bone and mineral metabolism disorders.Objectives: This investigation studied the bone mineral density (BMD) and bone metabolism biochemical markers in patients with CKD at the hemodialysis treatment among a group of Iranian hemodialysis patients. We also sought to test the possible association of risk factors and biochemical parameters with BMD.Patients and Methods: In this cross sectional study, 77 patients with CKD stage 5D at the hemodialysis treatment. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the anteroposterior lumbar spine (LS) (L1-L4) and left proximal femur. Biochemical markers, including calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), serum specific alkaline phosphatase (ALP) and 25-hydroxy-vitamin D (25(OH)D) were measured to assess BMD loss.Results: Around two (2.6%) patients had normal levels of 25(OH) D (mean levels 17.67 ± 11.66 nmol/l). We found a reduction of BMD in comparison with age and gender-matched normal population values at the femoral neck (FN) (T-score = -1.92 ± 1.29), at the total hip (TH) (T-score = -1.79 ± 1.25) and at the lumbar spine (LS) (T-score = -1.55 ± 1.84). The prevalence of T-scores ≤ -2.5 SD was 28.6%, 35.1% and 13.0% according to LS, FN and three bone sites T scores respectively. BMD negatively correlated: with age at the proximal femur, with serum ALP at the lumbar spine and with age of menopause at the femoral neck.Conclusion: Patients with end-stage renal disease at the hemodialysis treatment had a high prevalence of osteoporosis in the general population. Bone mineral density at the all bone sites was below the expected average for gender and age.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"14 1","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2017-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82178532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alireza Nematollahi, M. Tamadon, P. Irannejad, Milad Fouladgar, M. Bahadoram, Saeed Mardani
Introduction: Dialysis patients tend to have a greater prevalence of cardiovascular diseases. Objectives: The aim of this study was to determine the prevalence of heart valve calcification, left ventricular hypertrophy, and left ventricular systolic and diastolic dysfunction. It also aimed to determining the relationship of the above mentioned parameters with serum calcium, phosphorus, parathormon and duration of dialysis. Patients and Methods: This cross-sectional study was conducted on 100 hemodialysis patients who were referred to Hajar hospital in Shahrekord, Iran. Using echocardiography, patients were examined for the calcification of the heart valves, left ventricular hypertrophy, and left ventricular systolic and diastolic dysfunction. Serum calcium, phosphorus, and parathormon and duration of dialysis was also determined. Results: The mean age of the patients was 58.10 ± 15.51 years. Around 24 patients suffered from calcification of the heart valves. Additionally, 85 patients suffered from left ventricular hypertrophy. The prevalence of left ventricular systolic and diastolic dysfunction was 26% and 86%, respectively. Common valvular abnormalities were mitral valve regurgitation (97%), followed by tricuspid regurgitation and aorta-pulmonary disorder, respectively. There was a significant relationship between serum phosphate and calcification of cardiac valves, left ventricular hypertrophy, and left ventricular systolic dysfunction (P 0.05). Conclusion: Cardiovascular diseases are common among hemodialysis patients. Hyperphosphatemia is a risk factor for the prevalence of left ventricular hypertrophy, left ventricular systolic dysfunction and calcification of the heart valves.
{"title":"Association of serum phosphorus, calcium and parathyroid hormone with cardiovascular calcification in regular hemodialysis patients","authors":"Alireza Nematollahi, M. Tamadon, P. Irannejad, Milad Fouladgar, M. Bahadoram, Saeed Mardani","doi":"10.15171/JPD.2018.17","DOIUrl":"https://doi.org/10.15171/JPD.2018.17","url":null,"abstract":"Introduction: Dialysis patients tend to have a greater prevalence of cardiovascular diseases. Objectives: The aim of this study was to determine the prevalence of heart valve calcification, left ventricular hypertrophy, and left ventricular systolic and diastolic dysfunction. It also aimed to determining the relationship of the above mentioned parameters with serum calcium, phosphorus, parathormon and duration of dialysis. Patients and Methods: This cross-sectional study was conducted on 100 hemodialysis patients who were referred to Hajar hospital in Shahrekord, Iran. Using echocardiography, patients were examined for the calcification of the heart valves, left ventricular hypertrophy, and left ventricular systolic and diastolic dysfunction. Serum calcium, phosphorus, and parathormon and duration of dialysis was also determined. Results: The mean age of the patients was 58.10 ± 15.51 years. Around 24 patients suffered from calcification of the heart valves. Additionally, 85 patients suffered from left ventricular hypertrophy. The prevalence of left ventricular systolic and diastolic dysfunction was 26% and 86%, respectively. Common valvular abnormalities were mitral valve regurgitation (97%), followed by tricuspid regurgitation and aorta-pulmonary disorder, respectively. There was a significant relationship between serum phosphate and calcification of cardiac valves, left ventricular hypertrophy, and left ventricular systolic dysfunction (P 0.05). Conclusion: Cardiovascular diseases are common among hemodialysis patients. Hyperphosphatemia is a risk factor for the prevalence of left ventricular hypertrophy, left ventricular systolic dysfunction and calcification of the heart valves.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"63 1","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2017-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83439684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The parathyroid disorder is an important problem in clinical endocrinology. There are several possible causes of parathyroid disorder. Infection is an uncommon cause of parathyroid disorder. The parasitic infection induced parathyroid disorder is an important problem in tropical medicine. In this paper, the authors briefly summarize and discuss on the important abnormalities of parathyroid due to important tropical parasitic infections.
{"title":"Abnormal parathyroid in some important tropical parasitic infections: a new trend","authors":"S. Yasri, V. Wiwanitkit","doi":"10.15171/JPD.2018.16","DOIUrl":"https://doi.org/10.15171/JPD.2018.16","url":null,"abstract":"The parathyroid disorder is an important problem in clinical endocrinology. There are several possible causes of parathyroid disorder. Infection is an uncommon cause of parathyroid disorder. The parasitic infection induced parathyroid disorder is an important problem in tropical medicine. In this paper, the authors briefly summarize and discuss on the important abnormalities of parathyroid due to important tropical parasitic infections.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"28 1","pages":"42-43"},"PeriodicalIF":0.0,"publicationDate":"2017-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75490652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Calcium and vitamin D supplements intake have been linked to nephrolithiasis as around 80% of kidney stones contain calcium. However, studies regarding these supplements administration yielded conflicting data. Objectives: In this study we aimed to assess calcium and vitamin D supplements intake and the presence of significant association with nephrolithiasis among Lebanese patients. Patients and Methods: The study was conducted at nephrology clinics selected randomly from all Lebanese districts over a 3-month period. Data analysis was conducted with SPSS version 22. Results: The mean age of the 550 studied participants was 42.12±15.59 years with 51.5% males and 48.5% females. Almost half of the participants had a history of kidney stones (53.8%). Calcium and vitamin D supplements were utilized by 19.6% and 18.2%, respectively. Calcium and vitamin D supplements intake were not associated significantly with history of kidney stones (calcium: 10.4% versus 9.3%, P = 0.446; vitamin D: 9.1% versus 9.1%, P = 0.231). Conclusion: This study revealed that supplemental calcium and vitamin D intake among nephrolithiasis patients had no significant associations with history of kidney stones. Those patients, especially those taking calcium supplements should be counseled to monitor regularly their calcium levels to avoid hypercalciuria and consequent stone formation.
导读:钙和维生素D补充剂的摄入与肾结石有关，因为大约80%的肾结石含有钙。然而，关于这些补充剂管理的研究产生了相互矛盾的数据。目的:在本研究中，我们旨在评估黎巴嫩患者中钙和维生素D补充剂的摄入量及其与肾结石的显著相关性。患者和方法:研究在黎巴嫩所有地区随机选择的肾科诊所进行，为期3个月。数据分析采用SPSS 22。结果:550名研究对象的平均年龄为42.12±15.59岁，其中男性51.5%，女性48.5%。几乎一半的参与者有肾结石病史(53.8%)。钙和维生素D补充剂的使用率分别为19.6%和18.2%。钙和维生素D补充剂的摄入与肾结石病史无显著相关性(钙:10.4% vs 9.3%， P = 0.446;维生素D: 9.1%对9.1%，P = 0.231)。结论:本研究显示，肾结石患者补充钙和维生素D的摄入量与肾结石病史无显著相关性。这些患者，特别是那些服用钙补充剂的患者，应定期监测他们的钙水平，以避免高钙尿症和随之而来的结石形成。
{"title":"Calcium and vitamin D supplements administration in patients with nephrolithiasis; an observational prospective study","authors":"M. Akel, Iqbal M. Fahs","doi":"10.15171/JPD.2018.15","DOIUrl":"https://doi.org/10.15171/JPD.2018.15","url":null,"abstract":"Introduction: Calcium and vitamin D supplements intake have been linked to nephrolithiasis as around 80% of kidney stones contain calcium. However, studies regarding these supplements administration yielded conflicting data. Objectives: In this study we aimed to assess calcium and vitamin D supplements intake and the presence of significant association with nephrolithiasis among Lebanese patients. Patients and Methods: The study was conducted at nephrology clinics selected randomly from all Lebanese districts over a 3-month period. Data analysis was conducted with SPSS version 22. Results: The mean age of the 550 studied participants was 42.12±15.59 years with 51.5% males and 48.5% females. Almost half of the participants had a history of kidney stones (53.8%). Calcium and vitamin D supplements were utilized by 19.6% and 18.2%, respectively. Calcium and vitamin D supplements intake were not associated significantly with history of kidney stones (calcium: 10.4% versus 9.3%, P = 0.446; vitamin D: 9.1% versus 9.1%, P = 0.231). Conclusion: This study revealed that supplemental calcium and vitamin D intake among nephrolithiasis patients had no significant associations with history of kidney stones. Those patients, especially those taking calcium supplements should be counseled to monitor regularly their calcium levels to avoid hypercalciuria and consequent stone formation.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"1 1","pages":"39-41"},"PeriodicalIF":0.0,"publicationDate":"2017-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90979989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implication for health policy/practice/research/medical education Treatment for renal failure, especially those who undergo dialysis, is very difficult and challenging. Bisphosphonates have been administered for the treatment of osteoporosis for many years, but they are administered with caution in those who have renal failure. With the introduction of Prolia as an anti-osteoporosis drug, the hope was created to treat patients with kidney failure.
{"title":"Anti-receptor activator nuclear factor κ-B ligand (anti-RANKL) as an antiresorptive agent for renal failure osteoporotic patient","authors":"mansoor karimifar, M. Karimifar","doi":"10.15171/jpd.2018.12","DOIUrl":"https://doi.org/10.15171/jpd.2018.12","url":null,"abstract":"Implication for health policy/practice/research/medical education Treatment for renal failure, especially those who undergo dialysis, is very difficult and challenging. Bisphosphonates have been administered for the treatment of osteoporosis for many years, but they are administered with caution in those who have renal failure. With the introduction of Prolia as an anti-osteoporosis drug, the hope was created to treat patients with kidney failure.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"62 1","pages":"33-33"},"PeriodicalIF":0.0,"publicationDate":"2017-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74529528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic kidney disease mineral and bone disorder is a metabolic bone disease present in almost all uremic patients. There are no good markers of bone resorption available for uremic patients. The validity of parathormone as a surrogate marker of bone and mineral disorders has been questioned over the past decade. We need to shift from Surrogate markers to bone markers.
{"title":"The need for a reliable bone biomarker to better assess chronic kidney disease mineral and bone disorder","authors":"R. Tolouian, Ajay Gupta","doi":"10.15171/JPD.2018.14","DOIUrl":"https://doi.org/10.15171/JPD.2018.14","url":null,"abstract":"Chronic kidney disease mineral and bone disorder is a metabolic bone disease present in almost all uremic patients. There are no good markers of bone resorption available for uremic patients. The validity of parathormone as a surrogate marker of bone and mineral disorders has been questioned over the past decade. We need to shift from Surrogate markers to bone markers.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"79 1","pages":"36-38"},"PeriodicalIF":0.0,"publicationDate":"2017-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79309858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The use of new molecular diagnostic technique for detection of parathyroid cancer is very interesting (1). The new molecular approach is expected to be the effective biomarker tool for using as tumor marker. In Thailand, the new diagnostic tool has just been introduced for a few years. In a recent report, Niramitmahapanya et al mentioned that “HRPT2 mutations by SyBr Green PCR sensitive technique to identify parathyroid cancers or atypical adenoma from benign parathyroid tissue (2).” Here, the authors performed a cost analysis on the available for somatic and germline SyBr Green PCR method screening for parathyroid gland; a cost analysis in Thailand. The cost is referred to the data from tertiary referencing center in Bangkok, Thailand. The utility is according to the previous report by Niramitmahapanya et al, on using for somatic and germline SyBr Green PCR method screening for parathyroid gland in the tertiary referencing center in Bangkok (Rajvithi hospital), Thailand (2). According to this study, the cost and utility of somatic and germline SyBr Green PCR method screening for parathyroid gland is shown in Table 1. According to the cost analysis, the cost utility for using the new technique is still high and might DOI: 10.15171/jpd.2018.11
利用新的分子诊断技术检测甲状旁腺癌是非常有趣的(1)。新的分子方法有望成为有效的生物标志物工具，作为肿瘤标志物。在泰国，这种新的诊断工具刚刚被引入了几年。在最近的一份报告中，Niramitmahapanya等人提到“HRPT2突变通过SyBr Green PCR敏感技术从良性甲状旁腺组织中识别甲状旁腺癌或非典型腺瘤(2)”。在这里，作者对可用的用于体细胞和种系SyBr Green PCR方法筛选甲状旁腺的成本进行了分析;泰国的成本分析。费用参考泰国曼谷三级参考中心的数据。根据Niramitmahapanya等人之前的报告，在泰国曼谷(Rajvithi医院)的三级参考中心使用体细胞和种系SyBr Green PCR方法筛选甲状旁腺(2)。根据本研究，体细胞和种系SyBr Green PCR方法筛选甲状旁腺的成本和效用如表1所示。根据成本分析，使用新技术的成本效用仍然很高，并且可能
{"title":"Cost analysis for somatic and germline SyBr Green PCR method screening for parathyroid gland; a cost analysis from Thailand","authors":"S. Yasri, V. Wiwanitkit","doi":"10.15171/JPD.2018.11","DOIUrl":"https://doi.org/10.15171/JPD.2018.11","url":null,"abstract":"The use of new molecular diagnostic technique for detection of parathyroid cancer is very interesting (1). The new molecular approach is expected to be the effective biomarker tool for using as tumor marker. In Thailand, the new diagnostic tool has just been introduced for a few years. In a recent report, Niramitmahapanya et al mentioned that “HRPT2 mutations by SyBr Green PCR sensitive technique to identify parathyroid cancers or atypical adenoma from benign parathyroid tissue (2).” Here, the authors performed a cost analysis on the available for somatic and germline SyBr Green PCR method screening for parathyroid gland; a cost analysis in Thailand. The cost is referred to the data from tertiary referencing center in Bangkok, Thailand. The utility is according to the previous report by Niramitmahapanya et al, on using for somatic and germline SyBr Green PCR method screening for parathyroid gland in the tertiary referencing center in Bangkok (Rajvithi hospital), Thailand (2). According to this study, the cost and utility of somatic and germline SyBr Green PCR method screening for parathyroid gland is shown in Table 1. According to the cost analysis, the cost utility for using the new technique is still high and might DOI: 10.15171/jpd.2018.11","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"44 1","pages":"32-32"},"PeriodicalIF":0.0,"publicationDate":"2017-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77429276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implication for health policy/practice/research/medical education Primary hyperparathyroidism (PHPT) is an important abnormality of parathyroid gland. PHPT is usually diagnosed late
原发性甲状旁腺功能亢进(PHPT)是一种重要的甲状旁腺异常。PHPT通常诊断较晚
{"title":"The underlying pathology of primary hyperparathyroidism; a summary on 87 published cases in Thailand","authors":"S. Yasri, V. Wiwanitkit","doi":"10.15171/JPD.2018.13","DOIUrl":"https://doi.org/10.15171/JPD.2018.13","url":null,"abstract":"Implication for health policy/practice/research/medical education Primary hyperparathyroidism (PHPT) is an important abnormality of parathyroid gland. PHPT is usually diagnosed late","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"30 1","pages":"34-35"},"PeriodicalIF":0.0,"publicationDate":"2017-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85020394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：